NathanDM, GenuthS, LachinJ, et al.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329:977–986.
2.
BergenstalRM, Hachmann-NielsenE, KvistK, et al.Increased derived time in range is associated with reduced risk of major adverse cardiovascular events, severe hypoglycemia, and microvascular events in type 2 diabetes: A post hoc analysis of DEVOTE. Diabetes Technol Ther, 2023.
3.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Factors predictive of severe hypoglycemia in type 1 diabetes: Analysis from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized control trial dataset. Diabetes Care, 2011; 34:586–590.
4.
BeckRW, BergenstalRM, RiddlesworthTD, KollmanC. The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemia events: Analysis of the DCCT data set. Diabetes Technol Ther, 2019; 21:1–5.
5.
BeckRW, BergenstalRM, RiddlesworthTD, et al.Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care, 2019; 42:400–405.
6.
LachinJM, BebuI, GaoX, et al.Association of estimated time-in-range capillary glucose levels versus HbA1c with progression of microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care, 2022; 45:2445–2448.
7.
BeckRW, BergenstalRM, ChengP, et al.The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol, 2019; 13:614–626.
8.
BergenstalRM, BeckRW, CloseKL, et al.Glucose management indicator (GMI): A new term for estimating a1c from continuous glucose monitoring. Diabetes Care, 2018; 41:2275–2280.
9.
FabrisC, HeinemannL, BeckR, et al.Estimation of hemoglobin A1c from continuous glucose monitoring data in individuals with type 1 diabetes: Is time in range all we need?. Diabetes Technol Ther, 2020; 22:501–508.
10.
LuJ, MaX, ZhouJ, et al.Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care, 2018; 41:2370–2376.
11.
RanjanAG, RosenlundSV, HansenTW, et al.Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes. Diabetes Care, 2020; 43:2882–2885.
12.
YooJH, ChoiMS, AhnJ, et al.Association between continuous glucose monitoring-derived time in range, other core metrics, and albuminuria in type 2 diabetes. Diabetes Technol Ther, 2020; 22:768–776.
13.
MayedaL, KatzR, AhmadI, et al.Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care, 2020; 8:1–8.
14.
LuJ, HomePD, ZhouJ. Comparison of multiple cut points for time in range in relation to risk of abnormal carotid intima-media thickness and diabetic retinopathy. Diabetes Care, 2020; 43:e99–e101.
15.
GuoQ, ZangP, XuS, et al.Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardiovascular autonomic neuropathy independent of HbA1c in Chinese type 2 diabetes. J Diabetes Res, 2020; 2020:1–11.
16.
KimMY, KimG, ParkJY, et al.The association between continuous glucose monitoring-derived metrics and cardiovascular autonomic neuropathy in outpatients with type 2 diabetes. Diabetes Technol Ther, 2021; 23:434–442.
17.
El MalahiA, Van ElsenM, CharleerS, et al.Relationship between time in range, glycemic variability, HbA1c, and complications in adults with type 1 diabetes mellitus. J Clin Endocrinol Metab, 2022; 107:e570–e581.
18.
LuJ, WangC, ShenY, et al.Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: A prospective cohort study. Diabetes Care, 2021; 44:549–555.
19.
Beyond A1C Writing Group. Need for regulatory change to incorporate beyond A1C glycemic metrics. Diabetes Care, 2018; 41:e92–e94.
